The Italian biotechnology company ReiThera reported this week that its vaccine against the coronavirus under development generated an antibody response in a clinical test in 93% of volunteers after the first dose and in 99% after the second.
As the company explained in a statement, “antibody responses (seroconversion) against the SARS-CoV-2 spike protein were achieved in more than 93% of volunteers three weeks after the first dose, reaching 99% after the second dose.” .
Five weeks after the first vaccination, the level of antibodies was comparable to that of a person recovering from Covid-19 infection, he added.
As such, the independent advisory boards that monitor the results of these tests recommended moving to the next phase, which will be the third, according to the publication.
The study was carried out in 24 clinical centers in Italy, with 917 volunteers over the age of 18, and 25% of the people were over the age of 65 and/or had conditions associated with an increased risk of severe disease in case of SARS-CoV2 infection.
The volunteers were randomly distributed into three groups and, based on this, received a single dose of the vaccine followed by a dose of placebo; two doses of vaccine; or two doses of placebo, all with a three-week interval between the two administrations.
A italian company stated that “the vaccine was well tolerated in the first phase and even better in the second” and that the side effects were mostly “mild or moderate and short-lived”, just “pain at the injection site, fatigue, muscle aches and pains head”, highlighting that “there were no serious adverse incidents”.
The government of Espírito Santo is working to establish a partnership so that part of the phase 3 testing of the Italian compound can be carried out in Espírito Santo territory. The study foresees testing the vaccine on 30 people in the state.
FOLLOW-US
